Dublin, Nov. 24, 2023 (GLOBE NEWSWIRE) -- The "Ocular Hypertension - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Ocular Hypertension - Pipeline Insight, 2023" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Hypertension pipeline landscape is provided which includes the disease overview and Ocular Hypertension treatment guidelines. The assessment part of the report embraces, in depth Ocular Hypertension commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Ocular Hypertension.
Ocular Hypertension Emerging Drugs Chapters
This segment of the Ocular Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ocular Hypertension Emerging Drugs
NCX-470: Nicox
NCX 470, is a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in Phase III clinical development for the lowering of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.
It is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox's proprietary NO-donating research platform and bimatoprost in a single molecule. It is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension.
QLS-101: Qlaris Bio
QLS-101 is an investigational therapy, designed to lower intraocular pressure (IOP) by reducing episcleral venous pressure (EVP) in individuals with glaucoma. It is currently in Phase II trial in adolescents with Sturge-Weber syndrome (SWS) who have clinical evidence of glaucoma and/or ocular hypertension (OHT) related to SWS elevated EVP in at least one eye.
It is a novel adenosine triphosphate (ATP)-sensitive potassium (KATP) channel modulator administered as a topical eyedrop. Beyond its potential utility as an effective monotherapy or additive therapy for the lowering of IOP in primary open angle glaucoma (POAG), QLS-101 may represent a new treatment paradigm in additional populations where current IOP-lowering therapies are inadequate, including normal-tension glaucoma (NTG) and patients with Sturge-Weber syndrome (SWS, a rare pediatric disease).
TO-O-1001: TheratOcular Biotek Co., Ltd.
TO-O-1001 (Formerly known as MG-O-1001) eye drops is a patented new generation Rho kinase (ROCK) inhibitor for treating patients with primary open-angle glaucoma or ocular hypertension. Its therapeutic potency is established through a dual-targeting mechanism, which in turn leads to relaxation of the cells of trabecular meshwork and the inner walls of Schlemm's canal. It is currently in Phase I/II for Patients with Open-Angle Glaucoma or Ocular Hypertension.
Its unique features include novel and proven working mechanism, good for used alone or in combination with the other IOP-lowering agents, best in class as the ROCK inhibition is a proven clinical approach for lowering IOP, animal studies showed superior efficacy results in IOP-lowering than the current market leader, and user-friendly as once a day.
Ocular Hypertension: Therapeutic Assessment
This segment of the report provides insights about the different Ocular Hypertension drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Ocular Hypertension
There are approx. 70+ key companies which are developing the therapies for Ocular Hypertension. The companies which have their Ocular Hypertension drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.
Ocular Hypertension: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ocular Hypertension therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Hypertension drugs.
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ocular Hypertension drugs?
- How many Ocular Hypertension drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ocular Hypertension?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ocular Hypertension therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ocular Hypertension and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Nicox
- Qlaris Bio
- TheratOcular Biotek Co., Ltd.
- Ocular Therapeutix
- Whitecap Biosciences, LLC
- JeniVision, Inc.
- AbbVie
Key Products
- NCX-470
- QLS-101
- TO-O-1001
- OTX-TIC
- WB007
- JV-GL1
- AGN-193408
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Ocular Hypertension Report Insights
- Ocular Hypertension Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/6smdx7
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
